According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients. Increasingly impactful nature of research in JNCCN reflected in new high for the journal's Impact Factor, now 12.693. PLYMOUTH MEETING, Pa., Sept. 9, 2022 /PRNewswire/ New research in the September 2022 issue of JNCCN-Journal of the National Comprehensive Cancer Networkfinds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery. "We were astonished by how metabolic imaging can now predict outcomes with high accuracy before any surgical intervention," said senior research Mark J. Truty, MD, MS,
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced a collaboration with Pfizer and Myovant.
/PRNewswire/ Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or.
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis to.